IP Library Granted Patent US 8,524,759
Granted Patent B2
US 8,524,759 · App. 13/543,948 · Granted Sep 3, 2013

Phenylbutazone carrier formulation showing increased bioactivity in animals

Inventor: Douglas J. Gordon (Pleasant Grove, UT)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,759
App. No.
13/543,948
Granted
Sep 3, 2013
Kind
B2
Abstract

An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine.

Claims (37)

1. A phenylbutazone carrier composition for promoting consumption and improving sustained bioavailability of phenylbutazone to horses comprising:

a therapeutic dosage comprising 4 grams of phenylbutazone; and wherein the composition comprises, as a percentage of the weight of phenylbutazone:

about 2 percent artificial flavor;

about 3.5 percent saccharine;

about 1 percent aspartame;

about 2 percent sucralose; and

about 2 percent of a carbonate salt or bicarbonate salt.

2. The composition of claim 1 , wherein the salt comprises an alkaline earth carbonate.

3. The composition of claim 1 , wherein the salt comprises calcium carbonate.

4. The composition of claim 1 , wherein the salt comprises sodium bicarbonate.

5. The composition of claim 1 , further comprising an anti-caking agent.

6. A phenylbutazone carrier composition for providing sustained duration bioavailability of phenylbutazone to horses comprising:

a therapeutic dose comprising 4 grams of phenylbutazone; and

a salt selected from the group consisting of carbonate salts and bicarbonate salts added to the phenylbutazone in an amount of about 2 percent of the weight of the phenylbutazone to improve bioavailability.

7. The composition of claim 6 , wherein the salt comprises sodium bicarbonate.

8. The composition of claim 6 , wherein the salt comprises an alkaline earth carbonate.

9. The composition of claim 6 , wherein the salt comprises calcium carbonate.

10. The composition of claim 6 , further comprising artificial sweetener.

11. The composition of claim 6 , further comprising artificial flavor.

12. The composition of claim 6 , wherein the composition comprises, as a percentage of the weight of phenylbutazone:

about 4 percent saccharine;

between about 1 and 2 percent aspartame;

artificial flavoring; and

anti-caking agent.

13. The composition of claim 12 , wherein the composition further comprises, as a percentage of the weight of phenylbutazone, between about 2 and 4 percent sucralose.

14. A phenylbutazone carrier composition for improving consumption and providing extended duration bioavailability in animals comprising:

phenylbutazone; and, for each 100 grams of phenylbutazone further comprising:

about 2 grams of an alkaline earth metal carbonate salt or alkaline metal bicarbonate salt.

15. The composition of claim 14 , further comprising artificial flavoring.

16. The composition of claim 14 , further comprising anti caking agent.

17. The composition of claim 14 , further comprising artificial sweetener.

18. The composition of claim 17 , wherein the artificial sweetener comprises, for each 100 grams of phenylbutazone:

between about 2 and 4 grams of sucralose;

about 4 grams of saccharine; and

between about 1 and 2 grams of aspartame.

19. The composition of claim 14 , wherein the salt comprises, more specifically, an alkaline earth carbonate.

20. The composition of claim 14 , wherein the salt comprises, more specifically, calcium carbonate.

Assignments (2)
SECURITY INTEREST Recorded Mar 31, 2025
From: NOBLE PHARMA, LLC
To: APOGEM CAPITAL LLC, AS AGENT
Reel/Frame 070681/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: GORDON, DOUGLAS J.
To: NOBLE PHARMA, LLC
Reel/Frame 068954/0889 →
Continuity (3)
Continuation In Part 12608913 · Oct 29, 2009
Provisional Application 61227282 · Jul 21, 2009
Related Publication 20120277278A1 · Nov 1, 2012